問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital (在職)

Digestive System Department

Division of General Internal Medicine

Kaohsiung Municipal Gangshan Hospital (在職)

Digestive System Department

更新時間：2023-09-19

陳信成Chen, Shinn-Cherng
  • Principal Investigator
  • Clinical Trial Experience (year) 23 years 9 個月

Recruiting Trial

3Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

陳信成

List

22Cases

2019-11-01 - 2028-12-31

Phase III

Active
A Phase III, Multicenter, Randomized, Open-Label Study of Atezolizumab (Anti-PD-L1 Antibody) Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation

  • Condition/Disease

    Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation

  • Test Drug

    Atezolizumab, Bevacizumab

Participate Sites
5Sites

Recruiting5Sites

2008-06-01 - 2010-03-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Terminated12Sites

2018-11-01 - 2025-01-13

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2017-11-01 - 2021-05-20

Phase III

Completed
A Randomized, Open-label, Multi-center Phase 3 study to Compare the efficacy and Safety of BGB-A317 versus Sorafenib as First-Line Treatment in patients with Unresectable Hepatocellular Carcinoma

  • Condition/Disease

    unresectable HCC

  • Test Drug

    Tislelizumab

Participate Sites
11Sites

Terminated9Sites

趙毅
Taipei Veterans General Hospital

Division of Hematology & Oncology

2019-01-24 - 2020-07-31

Phase II

Completed
Phase 1/2 Study of TAS-120 in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations

  • Condition/Disease

    Advanced Solid Tumors

  • Test Drug

    TAS-120

Participate Sites
5Sites

Not yet recruiting3Sites

Recruiting2Sites

2019-11-30 - 2026-09-30

Phase III

Active
xxxxxx

  • Condition/Disease

    xxxxxx

  • Test Drug

    xxxxxx

Participate Sites
9Sites

Recruiting9Sites

2006-10-18 - 2008-06-30

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

2019-01-01 - 2025-12-31

Phase I

Completed
Phase 1-2 Study of ADI PEG 20 plus FOLFOX in Subjects with Advanced Gastrointestinal Malignancies Focusing on Hepatocellular Carcinoma (HCC)

  • Condition/Disease

    Hepatocellular carcinoma

  • Test Drug

    ADI-PEG20

Participate Sites
13Sites

Terminated12Sites

楊再勝
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

趙毅
Taipei Veterans General Hospital

Division of Hematology & Oncology

2020-07-01 - 2022-01-17

Phase I

A Phase 1/1b First-in-human Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of SAR439459 Administered Intravenously as Monotherapy and in Combination With Cemiplimab in Adult Patients With Advanced Solid Tumors

  • Condition/Disease

    Malignant Solid Tumor

  • Test Drug

    SAR439459

Participate Sites
3Sites

Recruiting1Sites

Terminated2Sites

2020-06-30 - 2024-10-11

Phase III

A randomized, open-label, multi-center phase III clinical study to evaluate the safety and efficacy of Toripalimab (JS001) combined with Bevacizumab versus Sorafenib as first-line therapy for advanced hepatocellular carcinoma (HCC)

  • Condition/Disease

    To verify the efficacy of Toripalimab combined with Bevacizumab as the firstline therapy for advanced hepatocellular carcinoma (HCC).

  • Test Drug

    Toripalimab (JS001)

Participate Sites
3Sites

Recruiting3Sites

1 2 3
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB